CIK 0001401040 · Non-accelerated filer<br>Smaller reporting company
DiaMedica Therapeutics Inc.
Sign in to watch- Ticker
- DMAC
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Canada (Federal Level)
- Entity type
- operating
- Phone
- (763) 496-5454
- Business address
- 301 CARLSON PARKWAY, SUITE 210, MINNEAPOLIS, MN, 55305
- Former names
- DiaMedica Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-06-23 | Kellen Scott CFO and Secretary | Purchase | +10,000 | $3.91 | $39K | 32,290 |
| 2023-06-23 | Wambeke David J. Chief Business Officer | Purchase | +38,364 | $3.91 | $150K | 507,114 |
| 2023-06-23 | Pilnik Richard D. Director | Purchase | +38,363 | $3.91 | $150K | 248,245 |
| 2023-06-01 | Daves Julie VanOrsdel SVP Clinical Development Oper. | Grant or award · Stock Option (right to buy) | +54,000 | 54,000 | ||
| 2023-06-01 | Cundari Dominic R Chief Commercial Officer | Grant or award · Stock Option (right to buy) | +27,000 | 27,000 | ||
| 2023-06-01 | Gruis Kirsten L Chief Medical Officer | Grant or award · Stock Option (right to buy) | +67,000 | 67,000 | ||
| 2023-06-01 | Kellen Scott CFO and Secretary | Grant or award · Stock Option (right to buy) | +67,000 | 67,000 | ||
| 2023-06-01 | Pauls Dietrich John President and CEO | Grant or award · Stock option (right to buy) | +181,000 | 181,000 | ||
| 2023-06-01 | Semba Charles Pauling Director | Grant or award · Stock Option (right to buy) | +16,968 | 16,968 | ||
| 2023-06-01 | Pilnik Richard D. Director | Grant or award · Stock Option (right to buy) | +22,355 | 22,355 | ||
| 2023-06-01 | Parsons James T. Director | Grant or award · Stock Option (right to buy) | +16,968 | 16,968 | ||
| 2023-06-01 | Lewis Tanya Director | Grant or award · Stock Option (right to buy) | +7,493 | 7,493 | ||
| 2023-06-01 | Giuffre Randall Michael Director | Grant or award · Stock Option (right to buy) | +16,968 | 16,968 | ||
| 2023-05-30 | Kuntz Richard Director | Grant or award · Stock option (right to buy) | +32,320 | 32,320 | ||
| 2023-04-10 | Wambeke David J. Chief Business Officer | Purchase | +468,750 | $1.60 | $750K | 468,750 |
| 2023-04-10 | Wambeke David J. Chief Business Officer | Grant or award · Stock Option (right to buy) | +140,000 | 140,000 | ||
| 2023-03-01 | Lewis Tanya Director | Grant or award · Stock option (right to buy) | +26,443 | 26,443 | ||
| 2023-01-03 | Giuffre Randall Michael Director | Grant or award | +35,130 | $1.53 | $54K | 295,355 |
| 2023-01-03 | Burroughs Amy L. Director | Grant or award | +17,156 | $1.53 | $26K | 73,288 |
| 2023-01-03 | Semba Charles Pauling Director | Grant or award | +17,156 | $1.53 | $26K | 17,156 |
Page 5 of 10 · 189 trades